The clot-preventing drug by the Pfizer/Bristol Myers partnership is already approved in Europe and will likely be approved domestically before the end of Q1-13.
Drug seen as safe, effective for extended use-researchers
* Recurrence or death 3.8 pct for low dose; 4.2 pct for high
* Rate for placebo group was 11.6 percent
* Major bleeding extremely low with apixaban in year-long study
By Bill Berkrot
Dec 8 (Reuters) - A new blood clot preventer from Pfizer Inc and Bristol-Myers Squibb Co reduced the risk of recurrence of clots in veins and lungs and death by 80 percent with no increase in major bleeding in a study testing extended use of the drug.
In the year-long trial of 2,486 patients who had been previously treated for the condition known as venous thromboembolism (VTE) the drug, apixaban, met the combined primary goal by significantly reducing the recurrence of blood clots and death from any cause compared with a placebo, according to data presented at the American Society of Hematology (ASH) meeting in Atlanta, Georgia.